AMG 221 is an orally-administered small molecule antagonist of 11-beta hydroxysteroid dehydrogenase type 1 (“11ß-HSD1”), an enzyme associated with conversion of cortisone to cortisol in the liver and adipose tissue. It is being investigated as a treatment of metabolic disorders, including type 2 diabetes.
 

This information is current as of February 6, 2009. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.